NASDAQ$GOSS
Gossamer Bio Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Gossamer Bio reported financial results for Q1 2023 and provided a business update.
Gossamer Bio announced its Q1 2023 financial results, reporting a net loss of $49.2 million, or $0.52 per share. The company had $201.9 million in cash, cash equivalents, and marketable securities as of March 31, 2023. They are focusing on the development of seralutinib for PAH treatment and expect to initiate a Phase 3 clinical trial in Q3 2023.
- Received feedback from FDA and EMA on planned registrational program for seralutinib following Phase 2 TORREY study.
- Registrational Phase 3 clinical trial in PAH patients expected to initiate in Q3 2023.
- Initial TORREY study open-label extension data expected mid 2023.
- Implemented operational restructuring to prioritize seralutinib development.
Headline financials
Revenue & EPS history
Gossamer Bio · Revenue · Quarterly
$17M
Revenue by segment
Gossamer Bio · $17M total across 1 segment · Q1 2026
- Collaborators$17M—100.0%
Forward guidance
Gossamer Bio anticipates initiating a Phase 3 clinical trial for seralutinib in Q3 2023 and expects current cash, cash equivalents, and marketable securities to fund operations for at least the next 12 months.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-1.1%
Avg return
30 days after
43%
13 / 30 earnings
Positive
+15.2%
Q4 2022
Best reaction
-15.6%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -34.9% | -50.9% | |
| Q4 2025 | -10.8% | -21.0% | -5.5% | |
| Q3 2025 | +2.2% | +16.9% | +44.2% | |
| Q2 2025 | -8.5% | -18.9% | +15.7% | |
| Q1 2025 | +1.0% | +9.5% | +18.1% | |
| Q4 2024 | +0.0% | +6.0% | -38.4% | |
| Q3 2024 | -0.9% | -4.4% | -15.1% | |
| Q2 2024 | +4.3% | +7.5% | +12.5% | |
| Q1 2024 | -3.2% | -5.0% | -23.2% | |
| Q4 2023 | +4.1% | -4.8% | -26.2% | |
| Q3 2023 | -12.0% | +4.7% | +73.1% | |
| Q2 2023 | -7.0% | -9.3% | -24.7% | |
| Q1 2023 | +3.7% | -11.8% | -7.4% | |
| Q4 2022 | +15.2% | +5.7% | -0.5% | |
| Q3 2022 | -0.8% | -4.2% | -14.9% | |
| Q2 2022 | +4.6% | +6.5% | +13.7% | |
| Q1 2022 | +12.5% | +34.2% | +9.5% | |
| Q4 2021 | +3.7% | +1.0% | -2.8% | |
| Q3 2021 | -1.4% | -9.1% | -16.6% | |
| Q2 2021 | -0.8% | +9.5% | +18.9% | |
| Q1 2021 | -0.7% | -0.7% | +1.7% | |
| Q4 2020 | -9.4% | -5.5% | -11.6% | |
| Q3 2020 | -0.9% | -1.3% | +4.2% | |
| Q2 2020 | +5.1% | +2.4% | -1.1% | |
| Q1 2020 | -15.6% | -11.5% | -27.8% | |
| Q4 2019 | +5.5% | +5.7% | +40.0% | |
| Q3 2019 | -4.3% | -1.2% | +12.4% | |
| Q2 2019 | -2.5% | +3.2% | +2.6% | |
| Q1 2019 | +1.3% | +3.7% | -3.9% | |
| Q4 2018 | -4.9% | -10.8% | -30.1% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro